Do prostate cancer nomograms give accurate information when applied to European patients?

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374–403.
   PubMed Web of Science ®Google Scholar
• Gosselaar C, Roobol MJ, Schroder FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU int 2005;95(2):231–7.
   PubMed Web of Science ®Google Scholar
• Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, et al. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol 2002;20(2):82–8.
   PubMedGoogle Scholar
• Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008;113(11):3075–99.
   PubMed Web of Science ®Google Scholar
• Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008;101(12):1513–18.
   PubMed Web of Science ®Google Scholar
• Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445–51.
   PubMed Web of Science ®Google Scholar
• Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, Shariat S, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171(5):1844–9; discussion 9.
   PubMed Web of Science ®Google Scholar
• Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90(10):766–71.
   PubMed Web of Science ®Google Scholar
• Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170(5):1798–803.
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJr, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98(10):715–17.
   PubMed Web of Science ®Google Scholar
• Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095–101.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117(22):5039–46.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005;173(6):1938–42.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JCJr, Amling CL, et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006;107(10):2384–91.
   PubMed Web of Science ®Google Scholar
• Ishizaki F, Hoque MA, Nishiyama T, Kawasaki T, Kasahara T, Hara N, et al. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy. Jpn J Clin Oncol 2011;41(11):1259–64.
   PubMed Web of Science ®Google Scholar
• May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, et al. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a European multicenter survey of 1,296 patients. J Urol 2007;178(5):1957–62; discussion 62.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009. p 336.
   Google Scholar
• Katz MS, Efstathiou JA, D’Amico AV, Kattan MW, Sanda MG, Nguyen PL, et al. The “CaP Calculator”: an online decision support tool for clinically localized prostate cancer. BJU Int 2010;105(10):1417–22.
   PubMed Web of Science ®Google Scholar
• Eng J. ROC analysis: web-based calculator for ROC curves. Baltimore, MD: Johns Hopkins University; 2011.
   Google Scholar
• Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005;97(15):1132–7.
   PubMedGoogle Scholar
• D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969–74.
   PubMed Web of Science ®Google Scholar
• Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21(19):3573–9.
   PubMed Web of Science ®Google Scholar
• Mitchell RE, Shah JB, Desai M, Mansukhani MM, Olsson CA, Benson MC, et al. Changes in prognostic significance and predictive accuracy of Gleason grading system throughout PSA era: impact of grade migration in prostate cancer. Urology 2007;70(4):706–10.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Presti JCJr, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003;61(4):736–41.
   PubMed Web of Science ®Google Scholar
• Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F. Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 2005;95(8):1146–52.
   PubMed Web of Science ®Google Scholar
• Thanigasalam R, Rasiah KK, Stricker PD, Haynes AM, Sutherland SI, Sutherland RL, et al. Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram. BJU Int 2010;105(5):642–7.
   PubMed Web of Science ®Google Scholar
• Abbod MF, Catto JW, Linkens DA, Hamdy FC. Application of artificial intelligence to the management of urological cancer. J Urol 2007;178(4 Pt 1):1150–6.
   PubMed Web of Science ®Google Scholar
• Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013;111(1):22–9.
   PubMed Web of Science ®Google Scholar